Dr Tanguy Seiwert presents the results of a 132-patient study that indicates that pembrolizumab immunotherapy is effective for patients with recurrent or metastatic head and neck cancer (HNC) during a press conference at ASCO 2015.
Read the news article or watch Dr Lynn Schuchter's comment for more.